Literature DB >> 15072892

Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.

Matthew R Smith1.   

Abstract

OBJECTIVES: To assess the effects of androgen deprivation therapy on body composition in men with nonmetastatic prostate cancer.
METHODS: In a multicenter study, men with Stage M0 prostate cancer were prospectively evaluated during initial androgen deprivation therapy (gonadotropin-releasing hormone agonist or bilateral orchiectomy). The main outcomes were changes in weight, percentage fat mass, and percentage lean mass from baseline to 12 months.
RESULTS: Seventy-nine subjects were assessed. Serum testosterone concentrations decreased by 79.7% +/- 3.0% (P <0.001). Weight increased by 1.8% +/- 0.5% (P <0.001). The percentage fat mass increased by 11.0% +/- 1.7%, and the percentage lean mass decreased by 3.8% +/- 0.6% (P <0.001 for each comparison).
CONCLUSIONS: Androgen deprivation therapy increased weight and fat mass and decreased lean mass in men with nonmetastatic prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072892     DOI: 10.1016/j.urology.2003.10.063

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  85 in total

1.  Cardiac and cognitive effects of androgen deprivation therapy: are they real?

Authors:  S M H Alibhai; H Z Mohamedali
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

2.  Sarcopenia during androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Fred Saad; Blair Egerdie; Paul R Sieber; Teuvo L J Tammela; Chunlei Ke; Benjamin Z Leder; Carsten Goessl
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

Review 3.  Energetics in colorectal and prostate cancer.

Authors:  Jeffrey A Meyerhardt; Jing Ma; Kerry S Courneya
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

4.  Physical activity, sedentary behavior, and health-related quality of life in prostate cancer survivors in the health professionals follow-up study.

Authors:  Siobhan M Phillips; Meir J Stampfer; June M Chan; Edward L Giovannucci; Stacey A Kenfield
Journal:  J Cancer Surviv       Date:  2015-04-16       Impact factor: 4.442

5.  Prostate cancer reduces endurance exercise capacity in association with reductions in cardiac and skeletal muscle mass in the rat.

Authors:  Peter J Esau; Elizabeth M Gittemeier; Alexander B Opoku-Acheampong; Korynne S Rollins; Dryden R Baumfalk; David C Poole; Timothy I Musch; Bradley J Behnke; Steven W Copp
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 6.  A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants.

Authors:  Lene Thorsen; Kerry S Courneya; Clare Stevinson; Sophie D Fosså
Journal:  Support Care Cancer       Date:  2008-02-15       Impact factor: 3.603

Review 7.  Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.

Authors:  Heather L McGinty; Kristin M Phillips; Heather S L Jim; Julie M Cessna; Yasmin Asvat; Mallory G Cases; Brent J Small; Paul B Jacobsen
Journal:  Support Care Cancer       Date:  2014-05-25       Impact factor: 3.603

8.  Novel physical activity interventions for older patients with prostate cancer on hormone therapy: A pilot randomized study.

Authors:  Saleha Sajid; William Dale; Karen Mustian; Ashwin Kotwal; Charles Heckler; Michelle Porto; Chunkit Fung; Supriya G Mohile
Journal:  J Geriatr Oncol       Date:  2016-02-23       Impact factor: 3.599

Review 9.  Management of complications of androgen deprivation therapy in the older man.

Authors:  Supriya G Mohile; Karen Mustian; Kathryn Bylow; William Hall; William Dale
Journal:  Crit Rev Oncol Hematol       Date:  2008-10-25       Impact factor: 6.312

10.  Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer.

Authors:  Philip J Saylor; Matthew R Smith; A James O'Malley; Nancy L Keating
Journal:  Eur Urol       Date:  2013-02-12       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.